Gattex, Revestive (teduglutide) is a protein pharmaceutical. Teduglutide was first approved as Gattex on 2012-08-30. It is used to treat short bowel syndrome in the USA. It has been approved in Europe to treat malabsorption syndromes. The pharmaceutical is active against glucagon-like peptide 2 receptor. Gattex's patents are valid until 2025-11-01 (FDA).
|Indication||malabsorption syndromes, short bowel syndrome|
|Drug Class||Peptides: GLP peptide analogs|